OptiLight, by Lumenis is the first and only light-based therapy that is approved by the United States Food and Drug Administration and listed by the Australian Therapeutic Goods Administration for management of dry eye disease due to meibomian gland dysfunction (MGD).
MGD is the leading cause of dry eye disease.
Designed by eye care professionals for eye care professionals, every element offers a precise and comfortable dry eye procedure.
The patented pen-like handpiece has been designed to get as close to the lid margin as possible and is customised to fit every curve of the face. OptiLight’s embedded settings, which are based on Lumenis’ clinically validated treatment protocols, ensure safer and more effective patient procedures. The ergonomic intense pulse light handpiece is used for larger areas to successfully break dry eye’s vicious cycle of inflammation.
Contact: Lumenis (AUS) 1800 586 364, (NZ) 0800 239 015 or infoau@lumenis.com
